Literature DB >> 20540156

Phase I/II study of single-agent bortezomib for the treatment of patients with myelofibrosis. Clinical and biological effects of proteasome inhibition.

Giovanni Barosi, Elisabetta Gattoni, Paola Guglielmelli, Rita Campanelli, Fabio Facchetti, Simona Fisogni, Judith Goldberg, Roberto Marchioli, Ronald Hoffman, Alessandro M Vannucchi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20540156      PMCID： PMC2947025          DOI： 10.1002/ajh.21754

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  28 in total

1.  Anti-angiogenic effect of bortezomib in patients with multiple myeloma.

Authors:  Marianna Politou; Kikkeri Naresh; Evangelos Terpos; Danielle Crawley; Irvin Lampert; Jane F Apperley; Amin Rahemtulla
Journal:  Acta Haematol       Date:  2005       Impact factor: 2.195

2.  Quantitative evaluation of bone marrow angiogenesis in idiopathic myelofibrosis.

Authors:  Hongyu Ni; Giovanni Barosi; Ronald Hoffman
Journal:  Am J Clin Pathol       Date:  2006-08       Impact factor: 2.493

3.  Role for the nuclear factor kappaB pathway in transforming growth factor-beta1 production in idiopathic myelofibrosis: possible relationship with FK506 binding protein 51 overexpression.

Authors:  Emiko Komura; Carole Tonetti; Virginie Penard-Lacronique; Hédia Chagraoui; Catherine Lacout; Jean Pierre Lecouédic; Philippe Rameau; Najet Debili; William Vainchenker; Stéphane Giraudier
Journal:  Cancer Res       Date:  2005-04-15       Impact factor: 12.701

4.  Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines.

Authors:  Belén Blanco; José A Pérez-Simón; Luis I Sánchez-Abarca; Xonia Carvajal-Vergara; Juan Mateos; Belén Vidriales; Natalia López-Holgado; Patricia Maiso; Mercedes Alberca; Eva Villarón; David Schenkein; Atanasio Pandiella; Jesús San Miguel
Journal:  Blood       Date:  2005-11-10       Impact factor: 22.113

5.  Induction of apoptosis by proteasome inhibitors in B-CLL cells is associated with downregulation of CD23 and inactivation of Notch2.

Authors:  M Duechler; M Shehata; J D Schwarzmeier; A Hoelbl; M Hilgarth; R Hubmann
Journal:  Leukemia       Date:  2005-02       Impact factor: 11.528

Review 6.  International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).

Authors:  Ayalew Tefferi; Giovanni Barosi; Ruben A Mesa; Francisco Cervantes; H Joachim Deeg; John T Reilly; Srdan Verstovsek; Brigitte Dupriez; Richard T Silver; Olatoyosi Odenike; Jorge Cortes; Martha Wadleigh; Lawrence A Solberg; John K Camoriano; Heinz Gisslinger; Pierre Noel; Juergen Thiele; James W Vardiman; Ronald Hoffman; Nicholas C P Cross; D Gary Gilliland; Hagop Kantarjian
Journal:  Blood       Date:  2006-05-04       Impact factor: 22.113

7.  European consensus on grading bone marrow fibrosis and assessment of cellularity.

Authors:  Jürgen Thiele; Hans Michael Kvasnicka; Fabio Facchetti; Vito Franco; Jon van der Walt; Attilio Orazi
Journal:  Haematologica       Date:  2005-08       Impact factor: 9.941

8.  New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.

Authors:  Francisco Cervantes; Brigitte Dupriez; Arturo Pereira; Francesco Passamonti; John T Reilly; Enrica Morra; Alessandro M Vannucchi; Ruben A Mesa; Jean-Loup Demory; Giovanni Barosi; Elisa Rumi; Ayalew Tefferi
Journal:  Blood       Date:  2008-11-06       Impact factor: 22.113

9.  Proteasome inhibition induces apoptosis in primary human natural killer cells and suppresses NKp46-mediated cytotoxicity.

Authors:  Xiangling Wang; Astrid Ottosson; Chunyan Ji; Xiaoli Feng; Magnus Nordenskjöld; Jan-Inge Henter; Bengt Fadeel; Chengyun Zheng
Journal:  Haematologica       Date:  2009-02-19       Impact factor: 9.941

10.  A phase II study of bortezomib in patients with MALT lymphoma.

Authors:  Marlene Troch; Constanze Jonak; Leonhard Müllauer; Andreas Püspök; Michael Formanek; Wolfgang Hauff; Christoph C Zielinski; Andreas Chott; Markus Raderer
Journal:  Haematologica       Date:  2009-03-31       Impact factor: 9.941
View more
  9 in total

Review 1.  Setting Appropriate Goals for the Next Generation of Clinical Trials in Myelofibrosis.

Authors:  Giovanni Barosi
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

Review 2.  Preclinical models for drug selection in myeloproliferative neoplasms.

Authors:  Niccolò Bartalucci; Costanza Bogani; Alessandro M Vannucchi
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952

3.  Nuclear-Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis.

Authors:  Dongqing Yan; Anthony D Pomicter; Srinivas Tantravahi; Clinton C Mason; Anna V Senina; Jonathan M Ahmann; Qiang Wang; Hein Than; Ami B Patel; William L Heaton; Anna M Eiring; Phillip M Clair; Kevin C Gantz; Hannah M Redwine; Sabina I Swierczek; Brayden J Halverson; Erkan Baloglu; Sharon Shacham; Jamshid S Khorashad; Todd W Kelley; Mohamed E Salama; Rodney R Miles; Kenneth M Boucher; Josef T Prchal; Thomas O'Hare; Michael W Deininger
Journal:  Clin Cancer Res       Date:  2018-12-18       Impact factor: 12.531

4.  Ruxolitinib in combination with prednisone and nilotinib exhibit synergistic effects in human cells lines and primary cells from myeloproliferative neoplasms.

Authors:  Alicia Arenas Cortés; Rosa Ayala Diaz; Pilar Hernández-Campo; Julián Gorrochategui; Daniel Primo; Alicia Robles; María Luz Morales; Joan Ballesteros; Inmaculada Rapado; Miguel Gallardo; María Linares; Joaquín Martínez-López
Journal:  Haematologica       Date:  2018-12-13       Impact factor: 9.941

5.  Iron chelation therapy with deferasirox in the management of iron overload in primary myelofibrosis.

Authors:  Elena Maria Elli; Angelo Belotti; Andrea Aroldi; Matteo Parma; Pietro Pioltelli; Enrico Maria Pogliani
Journal:  Mediterr J Hematol Infect Dis       Date:  2014-06-01       Impact factor: 2.576

Review 6.  The Hepatocyte Growth Factor (HGF)/Met Axis: A Neglected Target in the Treatment of Chronic Myeloproliferative Neoplasms?

Authors:  Marjorie Boissinot; Mathias Vilaine; Sylvie Hermouet
Journal:  Cancers (Basel)       Date:  2014-08-12       Impact factor: 6.639

Review 7.  Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms.

Authors:  Daniel Arthur Corpuz Fisher; Jared Scott Fowles; Amy Zhou; Stephen Tracy Oh
Journal:  Front Immunol       Date:  2021-06-01       Impact factor: 8.786

Review 8.  Pathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic Inflammation.

Authors:  Sylvie Hermouet; Edith Bigot-Corbel; Betty Gardie
Journal:  Mediators Inflamm       Date:  2015-10-11       Impact factor: 4.711

Review 9.  Bone marrow niche dysregulation in myeloproliferative neoplasms.

Authors:  Natalia Curto-Garcia; Claire Harrison; Donal P McLornan
Journal:  Haematologica       Date:  2020-04-02       Impact factor: 9.941
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.